Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Public ClinicalTrials.gov record NCT03005782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).
Study identification
- NCT ID
- NCT03005782
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 333 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2016 (Actual)
- Primary completion
- Apr 2, 2024 (Actual)
- Completion
- Apr 2, 2024 (Actual)
- Last update posted
- May 1, 2024
2016 – 2024
United States locations
- U.S. sites
- 33
- U.S. states
- 20
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Associates for Research and Excellence | Encinitas | California | 92024 | — |
| California Cancer Associates For Research And Excellence | Fresno | California | 93720 | — |
| University of California San Diego (UCSD) | La Jolla | California | 92093-0698 | — |
| The Angeles Clinic | Los Angeles | California | 90025 | — |
| University of California Davis Health Systems | Sacramento | California | 95817 | — |
| California Pacific Medical Center (CPMC) | San Francisco | California | 94115 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Lombardi Comprehensive Cancer Center - MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Orlando Health, Inc | Orlando | Florida | 32806 | — |
| Winship Cancer Institute at Emory University | Atlanta | Georgia | 30322 | — |
| University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | — |
| Dana Farber Cancer Institute | Jamaica Plain | Massachusetts | 02130 | — |
| Henry Ford Health Hospital | Detroit | Michigan | 48202 | — |
| Cancer and Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49503 | — |
| Washington University in Saint Louis | St Louis | Missouri | 63110 | — |
| John Theurer Cancer Center, Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| New Mexico Cancer Care Alliance-UNM Cancer Center | Albuquerque | New Mexico | 87131 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Northwell Health-Monter Cancer Center | Lake Success | New York | 11042 | — |
| Laura & Isaac Perlmutter Cancer Center | New York | New York | 10016 | — |
| Columbia University | New York | New York | 10032 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| University Hospitals Seidman Cancer Center and Case Western Reserve University | Cleveland | Ohio | 44087 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Hollings Cancer Center - Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| South Texas Oncology and Hematology | San Antonio | Texas | 78229 | — |
| Virginia Cancer Care Specialist, PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03005782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2024 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03005782 live on ClinicalTrials.gov.